Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

• 期刊论文

• 发表日期：

  2024年1月5日

• Caicun Zhou,
• Ziping Wang,
• Meili Sun,
• Lejie Cao,
• Zhiyong Ma,
• Rong Wu,
• Yan Yu,
• Wenxiu Yao,
• Si Sun,
• Jianhua Chen,
• Wu Zhuang,
• Jiuwei Cui,
• Xueqin Chen,
• You Lu,
• Hong Shen,
• Chunhong Hu,
• Jiwei Liu,
• Yunpeng Liu,
• Mengzhao Wang,
• Xingya Li,
• Ping Sun,
• Yongqian Shu,
• Jianying Zhou,
• Jingzhang Li,
• Kangsheng Gu,
• Changli Wang,
• Hui Zhao,
• Yiping Zhang,
• Chunling Liu,
• Jingru Wang,
• Rumei Chen,
• Mengmeng Qin,
• Hao Wang,
• Jason Yang